NEW YORK (GenomeWeb) – Agendia announced today that it has signed an agreement to have Dutch genomic data analysis firm Bluebee provide data processing services for a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.
The kit allows Agendia's MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay to be performed by labs using existing NGS instruments, rather than sending them to the company for centralized processing. It is currently being validated with collaborators in anticipation of a European launch in early 2018.
According to Agendia, Bluebee will help provide secure global access to test kit results, while ensuring that all data complies with local data privacy and residency regulations. Additional terms of the deal were not disclosed.
"When choosing a data processing partner, it was important for us to work with a team that could deliver these results in a highly secure form," Marjolaine Baldo, Agendia's commercial vice president for Europe, the Middle East, and Africa, said in a statement. "We are very pleased to partner with Bluebee as we finalize the development of the MammaPrint BluePrint Kit ahead of European launch."